Customised micro-electrode array (MEA) test setup featuring a silicone-casted overlay with two chambers for separated cell seedings

Micro-electrode array (MEA) systems are noninvasive platforms for the investigation of electrophysiological properties of cell layers, such as spontaneously active cardiomyocytes. An MEA chip is composed of two-dimensional grids of dot-like electrodes embedded into glass. Here we present a test setup featuring a customised two-chamber silicone overlay. The overlay is designed to be placed on an MEA with two separate electrode fields and enables the seeding of two distinct cell sub-types on the MEA for synchronised drug testing applications while giving the possibility of analysing intersubtype-specific cellular interactions. The overlay has a full size of 10 x 10 x 5 mm (width x length x height), each chamber has a size of 2.5 x 6 x 5 mm (V = 75 mm³). The chambers are separated by a wall with a thickness of 0.3 mm. The overlay was manufactured via silicone-casting, utilising a 3D printed model. The model is 3D printed via high accurate digital light processing (DLP). In addition, a DLP 3D printed cover optimises the attachment of the overlay on an MEA. A proofof- principle of the utilisation of the overlay is demonstrated.

Human neuromuscular junction on micro-structured microfluidic devices implemented with a custom micro electrode array (MEA)

Microfluidic devices were coupled with custom MEA and used for co-culture of human motor neurons and muscles. This allowed to assess human NMJ activity by electrical stimulation of axons and recording of subsequent muscle action potentials.

hiPSCs Derived Cardiac Cells for Drug and Toxicity Screening and Disease Modeling: What Micro- Electrode-Array Analyses Can Tell Us

Human induced pluripotent stem cell (iPSC)-derived cardiomyocytes (CM) have been intensively used in drug development and disease modeling. Since iPSC-cardiomyocyte (CM) was first generated, their characterization has become a major focus of research. Multi-/micro-electrode array (MEA) systems provide a non-invasive user-friendly platform for detailed electrophysiological analysis of iPSC cardiomyocytes including drug testing to identify potential targets and the assessment of proarrhythmic risk. Here, we provide a systematical overview about the physiological and technical background of micro-electrode array measurements of iPSC-CM. We introduce the similarities and differences between action- and field potential and the advantages and drawbacks of MEA technology. In addition, we present current studies focusing on proarrhythmic side effects of novel and established compounds combining MEA systems and iPSC-CM. MEA technology will help to open a new gateway for novel therapies in cardiovascular diseases while reducing animal experiments at the same time.